Journal of personalized medicine

Effects of Glucagon-like Peptide-1 Receptor Activators on Metabolism, Inflammation, and Heart Health in Rheumatoid Arthritis

Updated

Abstract

Glucagon-like peptide-1 receptor agonists () may improve disease activity and cardiometabolic risk factors in rheumatoid arthritis patients.

  • GLP-1RAs could reduce pro-inflammatory cytokine production and oxidative stress in synovial cells.
  • Observational studies indicate improvements in disease activity and inflammatory markers in patients treated with GLP-1RAs alongside immunosuppressive therapy.
  • Extensive randomized trials in metabolic populations show that GLP-1RAs improve glycemic control, induce weight loss, and lower blood pressure and atherogenic lipids.
  • Real-world data specific to RA suggest favorable trends in reducing cardiometabolic risk factors and thromboembolic events.
  • Current evidence is mostly heterogeneous and non-randomized, highlighting the need for dedicated trials.

Simplified

Key numbers

9 of 15
EULAR Response Rate
Patients achieving EULAR response after liraglutide treatment
10%
Weight Loss
Average weight loss in patients treated with over six months
HR 0.76
Risk Reduction for Thromboembolic Events
Hazard ratio for overall thromboembolic events in patients using vs. DPP-4 inhibitors

Full Text

What this is

  • This scoping review examines the potential effects of glucagon-like peptide-1 receptor agonists () in rheumatoid arthritis ().
  • It focuses on their impact on cardiovascular comorbidities, disease activity, and underlying immuno-metabolic mechanisms.
  • , primarily used for type 2 diabetes and obesity, may offer benefits in managing due to their anti-inflammatory and metabolic effects.

Essence

  • may provide dual benefits in by addressing both metabolic dysfunction and inflammation. Evidence suggests improvements in disease activity and cardiovascular risk factors, although clinical data remain limited.

Key takeaways

  • have shown promise in improving disease activity in patients. Observational studies indicate that patients treated with experienced significant reductions in inflammatory markers and pain.
  • Clinical data suggest that may lower the risk of cardiovascular events in patients. Observational studies report reductions in thromboembolic events and overall mortality among those treated with .
  • The evidence base for in is heterogeneous and largely observational. Many studies are retrospective and lack randomization, highlighting the need for dedicated trials to confirm these findings.

Caveats

  • The current evidence is primarily observational and includes small sample sizes, limiting the ability to draw definitive conclusions about the efficacy of in .
  • Many studies do not adequately control for confounding factors, such as existing cardiovascular conditions and other treatments, which may influence outcomes.
  • Potential improvements in inflammatory outcomes could be indirectly related to weight loss and metabolic changes rather than direct effects of .

Definitions

  • GLP-1RAs: A class of medications that mimic the action of glucagon-like peptide-1, improving glucose metabolism and promoting weight loss.
  • RA: A chronic inflammatory disease characterized by joint inflammation and damage, often associated with increased cardiovascular risk.

Simplified

Funding

Competing interests

The authors declare no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free